CTRI/2018/06/014394招募中4 期
Effects of Add-On Treatment with Hydroxychloroquine on Glucose Fluctuations in Indian Type 2 Diabetes Patients Receiving Insulin with other oral therapy.
Dr Arjun Baidya0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •patients who are admitted to private hospital for hyperglycemia and during their hospitalization has achieved target glycemic control (7-9%) with Insulin and other oral therapy (Which include metformin, sulphonylureas, glinides, thiazolidine, DPP4i and alpha-glucosidase inhibitors).
- •Treatment with insulin therapy, including once-daily basal insulin, twice-daily premixed insulin therapy, or multiple daily insulin therapy, for at least 2 weeks. Daily insulin dosage <= 60 Units per day.
- •Patients with ideal body weight > 60 kg Compliance
- •Patient able to understand and willing to fully comply with study procedures and restrictions.
- •Patients ready to undergo a follow-up period of 9 days.
排除标准
- •Patients with a history of any retinopathy of any grade including diabetic retinopathy, evidence of an imminent need for retinal laser therapy, uncorrected visual acuity <20/100, abnormal visual fields, difficulty to examine optic disc, or evidence of retinal pigment epithelial abnormalities and patients with history or risk of macular edema.
- •Patients with history of myalgia, aplastic anemia or agranulocytosis, granulocytopenia, psoriasis, porphyria, rash, scaling, scaling eczema, and G6PD deficiency.
- •Patients with significant cardiovascular illness limiting participation of patient in a clinical trial
- •Patients with abnormal renal function (Serum Cr >1.5 mg/dL, BUN > 20 mg/dL).
- •Patients with abnormal liver function (AST and ALT, total bilirubin or alkaline phosphatase > 2.5 times the upper limit of normal values).
- •Patients with dementia or other cognitive impairment prohibiting informed consent.
- •Patients with disease of blood or haematopoetic organs
- •Patients with known history of HIV 1 or HIV 2, Hepatitis B or C Viruses or syphilis infection or malignancy.
- •Pregnant or lactating women
- •Women of childbearing potential not practicing contraception
研究者
相似试验
已完成
4 期
Hydroxychloroquine real world efficacy assessment as add on therapy compare to gliptin in IndiaCTRI/2018/06/014382Patna Medical College2,000
进行中(未招募)
不适用
Efficacy of the treatment with hydroxychloroquine in non responders HIV-infected HAART-treated patients - NDHIV infection (immunological nonresponders).MedDRA version: 9.1Level: LLTClassification code 10008922EUCTR2009-012499-28-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)40
尚未招募
3 期
Effect of hydroxychloroquine therapy in new-onset type 1 diabetesCTRI/2022/08/044961Post Graduate Institute of Medical Education and Research PGIMER Chandigarh
招募中
3 期
The prophylactic effect of oral hydroxy-chloroquine in close contacts of COVID-19 patientsIRCT20200513047426N1Boushehr University of Medical Sciences500
招募中
2 期
COVID-19 prophylaxis with hydroxychloroquine in Front-line Health and Allied-Health Care Workers: The COVID-SHIELD TrialCOVID-19 infectionInfection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620000501943Walter and Eliza Hall Institute of Medical Research650
